Back to Agenda
Luncheon Session: Protecting our Innovative Medicines: The Biopharmaceutical Industry’s Collaboration Against Doping Abuse in Sports ~ (Japanese Language Only)
Session Chair(s)
Tatsuya Kamiuchi
Risk Communication Department, Department Head
Chugai Pharmaceutical Co., Ltd., Japan
As illustrated by recent high-profile media reports, would-be dopers and their enablers find many ingenious and unethical ways to obtain and misuse medicines in a dangerous and unapproved manner for performance enhancement in sporting events. The fight against doping is thus a constant challenge for the biopharmaceutical industry as well as regulators, anti-doping agencies, sports organizations, and law enforcement agencies. The risks to individual athletes – both professional and amateur – of inappropriate, uncontrolled and unsafe use of medicines for doping are real and ever-present. Novel medicines are particularly attractive to would-be dopers precisely because they are new and are believed to be undetectable. The biopharmaceutical industry is ideally positioned to support anti-doping agencies in recognizing and addressing the misuse of new medicines. This session examines the opportunities for industry collaboration with antidoping agencies to identify and pre-empt potential doping abuse of new medicines and identifies areas for further development.
Speaker(s)
National Partnership Between an Anti-doping Agency and Pharmaceutical Industries for the Promotion of Sporting Integrity ~ (Japanese Language Only)
Takao Akama, MD, PhD
Japan Anti-Doping Agency (JADA), Japan
Vice President
The Biopharmaceutical Industry’s Collaboration Against Doping Abuse of Medicines in Sport – Recent Experience ~ (Japanese Language Only)
Tatsuya Kamiuchi
Chugai Pharmaceutical Co., Ltd., Japan
Risk Communication Department, Department Head
Have an account?